{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK1265744&page=2",
    "query": {
      "intervention": "GSK1265744",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK1265744&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T05:03:37.653Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04979728",
      "title": "HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Treatment",
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "At Home Self-Collections",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2021-05-27",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-09-26T05:03:37.653Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04979728"
    },
    {
      "nct_id": "NCT01848340",
      "title": "An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-associated Lipodystrophy Syndrome"
      ],
      "interventions": [
        {
          "name": "GSK1265744B (sodium salt) containing 14C-GSK1265744B",
          "type": "DRUG"
        },
        {
          "name": "150 mg GSK1265744B",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 16,
      "start_date": "2013-05",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2013-11-04",
      "last_synced_at": "2026-09-26T05:03:37.653Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848340"
    },
    {
      "nct_id": "NCT06145854",
      "title": "Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hiv"
      ],
      "interventions": [
        {
          "name": "Cabotegravir Injection [Apretude]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Midway Specialty Care Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2024-01-02",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-09-26T05:03:37.653Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Temple Terrace, Florida • West Palm Beach, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Temple Terrace",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06145854"
    },
    {
      "nct_id": "NCT02411435",
      "title": "Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "CAB",
          "type": "DRUG"
        },
        {
          "name": "RIF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2015-07",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2016-01-06",
      "last_synced_at": "2026-09-26T05:03:37.653Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02411435"
    },
    {
      "nct_id": "NCT02938520",
      "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir (CAB) tablet",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine (RPV) tablet",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir - Injectable Suspension (CAB LA)",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine - Injectable Suspension (RPV LA)",
          "type": "DRUG"
        },
        {
          "name": "ABC/DTG/3TC STR - Tablet",
          "type": "DRUG"
        },
        {
          "name": "DTG Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 631,
      "start_date": "2016-10-27",
      "completion_date": "2029-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-26T05:03:37.653Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02938520"
    },
    {
      "nct_id": "NCT02478463",
      "title": "Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir tablet 30 mg once daily for 28 days.",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 19,
      "start_date": "2017-02-27",
      "completion_date": "2019-07-25",
      "has_results": true,
      "last_update_posted_date": "2020-06-22",
      "last_synced_at": "2026-09-26T05:03:37.653Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02478463"
    },
    {
      "nct_id": "NCT01648257",
      "title": "Relative Bioavailability Study of GSK1265744 Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Human Immunodeficiency Virus and Hepatitis"
      ],
      "interventions": [
        {
          "name": "GSK1265744 Na Salt Tablets",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 Free Acid Nanomilled Capsules",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 Free Acid Micronized Capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 18,
      "start_date": "2012-08",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2016-08-12",
      "last_synced_at": "2026-09-26T05:03:37.653Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01648257"
    },
    {
      "nct_id": "NCT02799264",
      "title": "A Study to Evaluate the Effect of High Fat Meal on Cabotegravir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Cabotegravir 30 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2016-06",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-09-26T05:03:37.653Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02799264"
    },
    {
      "nct_id": "NCT02178800",
      "title": "Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK1265744 Tablets",
          "type": "DRUG"
        },
        {
          "name": "Injectable GSK1265744",
          "type": "DRUG"
        },
        {
          "name": "Placebo for GSK1265744 Tablets",
          "type": "DRUG"
        },
        {
          "name": "Injectable Placebo for GSK1265744",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 199,
      "start_date": "2015-02",
      "completion_date": "2018-07-13",
      "has_results": true,
      "last_update_posted_date": "2021-10-18",
      "last_synced_at": "2026-09-26T05:03:37.653Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178800"
    },
    {
      "nct_id": "NCT04001803",
      "title": "Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CAB LA+RPV LA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2019-07-08",
      "completion_date": "2022-03-18",
      "has_results": true,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-09-26T05:03:37.653Z",
      "location_count": 9,
      "location_summary": "Sacramento, California • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04001803"
    }
  ]
}